B. Riley raised the firm’s price target on Vanda Pharmaceuticals (VNDA) to $14 from $11 and keeps a Buy rating on the shares after the FDA approved Nereus for prevention of vomiting induced by motion sickness. The news supports the view that Vanda is an “ongoing turnaround story” trading at an “excessive discount” heading into two more potential approvals within the next 12 months, the analyst tells investors in a research note. Riley says that while the approval could unlock over $100M in peak revenue, the greater significance is in the implications for tradipitant approval in GLP-1 related nausea.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VNDA:
- Vanda motion sickness approval comes with ‘broad’ label, says Cantor
- Vanda Wins FDA Approval for NEREUS Motion Sickness Drug
- Vanda jumps 18% to $8.33 after motion sickness FDA approval
- Vanda receives FDA approval of Nereus for motion sickness
- Vanda Pharmaceuticals price target raised to $7.50 from $5 at Jefferies